Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | ACACA | Q13085 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3496850 | 0.99 | ACACB (0.43) | ACACBACACAHRH3 | |
| SCHEMBL13312102 | 0.84 | ACACB (0.35) | ACACBACACAHRH3 | |
| Hydrochloric Acid SCHEMBL3498400 | 0.83 | ACACB (0.35) | ACACBACACAHRH3 | |
| SCHEMBL13312109 | 0.81 | ACACB (0.34) | ACACBACACA | |
| SCHEMBL13311954 | 0.81 | ACACB (0.49) | ACACBACACA | |
| Hydrochloric Acid SCHEMBL3497266 | 0.80 | ACACB (0.34) | ACACBACACA | |
| Hydrochloric Acid SCHEMBL3497645 | 0.80 | ACACB (0.48) | ACACBACACA | |
| SCHEMBL3494921 | 0.80 | ACACB (0.48) | ACACBACACAHRH3 | |
| SCHEMBL13312036 | 0.79 | ACACB (0.42) | ACACBACACA | |
| Hydrochloric Acid SCHEMBL3496430 | 0.78 | ACACB (0.41) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2128163-A1 | SPIRO-RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | ACACB 6/4885ACACA 1/4885HRH3 4836/4885 |
| US-20100093777-A1 | SPIRO-RING COMPOUND | ACACA, PC, ACACB | ACACB 3/4885ACACA 1/4885HRH3 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.